Patent SG-11201900138T-A (SG)
Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
Inventor: RABINOVICH BRIAN
IPC: C07K16/28
Filed: 2017-07-07
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD HIM 011101011M 01 110 1001110111H 1101 MO IMEMOVOIMIE Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/009894 Al 11 January 2018 (11.01.2018) W I PO I PCT (51) International Patent Classification: (74) Agent: MACDOUGALL, Christina, A. et al.; Morgan, CO7K 16/28 (2006.01) Lewis & Bockius LLP, One Market, Spear Tower, San Fran- (21) International Application Number: cisco, CA 94105 (US). PCT/US2017/041241 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 07 July 2017 (07.07.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/359,612 07 July 2016 (07.07.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: IOVANCE BIOTHERAPEUTICS, INC. TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. [US/US]; 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, — (72) Inventors: RABINOVICH, Brian; 98 Hill Coutry Drive, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Stouffville, ON L4A 7X5 (CA). MARTIN-OROZCO, Na- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, talia; 98 Canterbury Hill Road, Action, MA 01720 (US). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, RADVANYI, Laszlo; 98 Canterbury Hill Road, Action, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MA 01720 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = Title: PROGRAMMED DEATH 1 LIGAND 1 (PD-L1) BINDING PROTEINS AND METHODS OF USE THEREOF — (54) = Figure 3 = 2 A 19E19-scFV-Fr 3 1 = = = — , = = = EC50 t -= 0,4039 - _ = = Maxibody Concentration (tog MA ,—, 7r C:7 GC (57) : The present disclosure provides proteins, such as antibodies, that include an antigen binding portion that specifically 01 binds to Programmed Death 1 Ligand 1 (PD-L1). Also provided are nucleic acids encoding the proteins, and cells (e.g., genetically modified cytotoxic lymphocytes) that include such nucleic acids. In some embodiments, a subject method includes reducing the inter- = - --- GC action between PD-L1 on a first-cell and PD-1 on a second cell. In some cases, the contacting is in vivo. For example, the methods and compositions provided can be used in the treatment of viral infection and cancer, such as the treatment of solid tumors via ACT or via C::::) administration of a subject protein that specifically binds to PD-L1. ei C [Continued on next page] WO 2018/009894 Al MIDEDIMOMOIDEIREEMOOVIRIMOIMOHIMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))